会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Assessment of oxidative stress in vivo
    • 体内氧化应激评估
    • US5891622A
    • 1999-04-06
    • US28543
    • 1998-02-24
    • Jason D. MorrowHyesook KimL. Jackson Roberts, IIDenis M. Callewaert
    • Jason D. MorrowHyesook KimL. Jackson Roberts, IIDenis M. Callewaert
    • G01N33/88C12Q1/00C12Q1/02C12Q1/26
    • G01N33/88
    • A method to assess oxidative stress in vivo by measuring the amount of free, esterified and glucuronidated forms of isoprostanes (8EPGF2) in a biological sample which contains the isoprostanes is disclosed. The method further includes determining the amount of total isoprostanes present in the sample. This amount is compared with a control sample. The oxidative stress is determined through the comparison wherein the amount of isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control. Alternatively the method of the present invention provides for only the measurement of the glucuronidated form wherein the amount of glucuronidated isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control.
    • 公开了一种通过测量包含异前列烷烷的生物样品中游离,酯化和葡糖醛酸化形式的异前列烷(8EPGF2)的量来评估体内氧化应激的方法。 该方法还包括测定样品中存在的总异前列烷烷的量。 将该量与对照样品进行比较。 通过比较确定氧化应激,其中与对照相比,从经历氧化应激的生物体分离的样品中异前列烷的量增加。 或者,本发明的方法仅提供葡萄糖醛酸化形式的测量,其中与对照相比,从与经历氧化应激的生物体分离的样品中葡萄糖醛酸化的异前列烷的量增加。
    • 3. 发明授权
    • Compositions, kits and methods for administration of antilipemic drugs
    • 抗疲劳药物的组合物,试剂盒和方法
    • US5981555A
    • 1999-11-09
    • US937669
    • 1997-09-26
    • Eric H. KuhrtsL. Jackson Roberts, IIJason D. Morrow
    • Eric H. KuhrtsL. Jackson Roberts, IIJason D. Morrow
    • A61K31/455A61K31/54A61K31/60A61K31/715A61K31/33
    • A61K31/60A61K31/455A61K31/54A61K31/621Y10S514/823
    • The present invention concerns composition, kits and methods for reducing the flushing effect (cutaneous erythema) of an antilipemic drug, for treating hyperlipemia, for improving the effectiveness of an anti-platelet aggregating drug (e.g., in nonresponders) and for treating thrombosis. The present compositions and kits for reducing the flushing effect and for treating hyperlipemia contain an antilipemic drug (such as niacin) and either a sustained release NSAID (such as aspirin) or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug. The kits contain (a) pre-dosages of the NSAID and optional carboxylic acid compound and (b) an antilipemic dosage of the antilipemic drug, which optionally may be combined with NSAID and optional carboxylic acid compound in an amount effective to maintain the reduction of the flushing effect. The present method of treating hyperlipemia comprises predosing the patient with a sustained release NSAID or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug at least 2 hours before administering the antilipemic drug. The present compositions and kits for increasing the effectiveness of an anti-platelet aggregating drug contain an NSAID such as aspirin, niacin or a congener thereof, and optionally, a carboxylic acid other than the NSAID, such as citric acid.
    • 本发明涉及用于降低抗血脂药物的冲洗作用(皮肤红斑),用于治疗高脂血症,改善抗血小板聚集药物(例如,在无应答者中)和用于治疗血栓形成的效果的组合物,试剂盒和方法。 用于降低冲洗效果和用于治疗高脂血症的本发明组合物和试剂盒含有抗血脂药物(例如烟酸)和持续释放的NSAID(例如阿司匹林)或NSAID和除NSAID和抗脂药物之外的羧酸化合物。 试剂盒包含(a)NSAID和任选的羧酸化合物的预先剂量和(b)抗脂药物的抗血药剂量,其任选地可以与NSAID和任选的羧酸化合物组合,其量有效地维持 冲洗效果。 本发明治疗高脂血症的方法包括在施用抗血脂药物前至少2小时预先给予具有持续释放NSAID或NSAID和除NSAID和抗脂药物之外的羧酸化合物的患者。 用于增加抗血小板聚集药物的有效性的本发明组合物和试剂盒含有NSAID,例如阿司匹林,烟酸或其同类物,以及任选的除NSAID之外的羧酸,例如柠檬酸。